MannKind Corp
MNKD
C$5.26
Share price
-3.54%
Change (1 day)
-34.75%
Change (1 year)
Categories
Revenue for MannKind Corp (MNKD)
Revenue in 2025 (TTM): C$0.41 Billion
According to MannKind Corp's latest financial reports the company's current revenue (TTM 
) is C$0.40 Billion. In 2024 the company made a revenue of C$0.40 Billion an increase over the revenue in the year 2023 that were of C$0.26 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for MannKind Corp from 2009 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | C$0.41 B | 1.71% |
| 2024 | C$0.40 B | 55.25% |
| 2023 | C$0.26 B | 94.92% |
| 2022 | C$0.13 B | 40.81% |
| 2021 | C$96.14 M | 15.75% |
| 2020 | C$83.06 M | 0.89% |
| 2019 | C$82.33 M | 116.95% |
| 2018 | C$37.94 M | 157% |
| 2017 | C$14.76 M | -93.71% |
| 2016 | C$0.23 B | |
| 2015 | N/A | |
| 2014 | N/A | |
| 2013 | N/A | -100% |
| 2012 | C$0.03 M | -31.57% |
| 2011 | C$0.05 M | -45.29% |
| 2010 | C$0.09 M | |
| 2009 | N/A |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Halozyme Therapeutics HALO | C$1.49 B | 264.36% | 🇺🇸 USA |
 Novo Nordisk NVO | C$60.21 B | 14,594.59% | 🇩🇰 Denmark |
 Merck MRK | C$88.01 B | 21,379.53% | 🇺🇸 USA |
 Eli Lilly LLY | C$67.47 B | 16,366.41% | 🇺🇸 USA |
 Nektar Therapeutics
NKTR | C$0.12 B | -70.68% | 🇺🇸 USA |
 Pfizer PFE | C$86.00 B | 20,889.26% | 🇺🇸 USA |